Development of c-MET pathway inhibitors (Q34198905)

31 July 2017

1 reference

title

Development of c-MET pathway inhibitors (English)

1 reference

31 July 2017

Xiangdong Liu

1

1 reference

31 July 2017

Robert C Newton

series ordinal

2

1 reference

31 July 2017

Peggy A Scherle

series ordinal

3

1 reference

31 July 2017

language of work or name

English

0 references

publication date

11 July 2011

1 reference

Expert Opinion on Investigational Drugs

31 July 2017

published in

1 reference

31 July 2017

volume

20

1 reference

31 July 2017

issue

9

1 reference

31 July 2017

page(s)

1225-1241

1 reference

Met, metastasis, motility and more

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Drug development of MET inhibitors: targeting oncogene addiction and expedience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Molecular cloning of a new transforming gene from a chemically transformed human cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Molecular cloning and expression of human hepatocyte growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Scatter factor is a fibroblast-derived modulator of epithelial cell mobility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Scatter factor/hepatocyte growth factor is essential for liver development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

c-Met confers protection against chronic liver tissue damage and fibrosis progression after bile duct ligation in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Sustained recruitment of phospholipase C-gamma to Gab1 is required for HGF-induced branching tubulogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Signaling networks assembled by oncogenic EGFR and c-Met

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Clinical correlations and prognostic relevance of HGF, VEGF AND FGF expression in Brazilian patients with non-Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Amplified met gene linked to double minutes in human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Amplification of the MET gene in glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Frequent amplification of the c-met gene in scirrhous type stomach cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Clinical implications of MET gene copy number in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Missense mutation of the MET gene detected in human glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Restoration of positioning control following Disabled-2 expression in ovarian and breast tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Somatic mutations lead to an oncogenic deletion of met in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Prognostic significance of c-Met expression in glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

MET overexpression turns human primary osteoblasts into osteosarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

c-met proto-oncogene expression in benign and malignant human prostate tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Identification of genes that modulate sensitivity of U373MG glioblastoma cells to cis-platinum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Novel therapeutic inhibitors of the c-Met signaling pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Molecularly targeted therapies for thyroid cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

The mutationally activated Met receptor mediates motility and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Targeting the HGF/SF receptor c-met using a hammerhead ribozyme transgene reduces in vitro invasion and migration in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Effect of c-Met Expression on Survival in Head and Neck Squamous Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.600687

Comparison of hepatocyte growth factor levels of epithelial ovarian cancer cyst fluids with benign ovarian cysts

21 January 2018

1 reference

3 January 2024

https://opencitations.net/index/api/v1/citations/10.1111/J.1048-891X.2004.14046.X

Identifiers

DOI

10.1517/13543784.2011.600687

1 reference

31 July 2017

1 reference